Cardiovascular and inflammatory effects of simvastatin therapy in patients with COPD: A randomized controlled trial

International Journal of COPD

Volumn 10, Issue , 2015, Pages 211-221

  John, Michelle E ^a   Cockcroft, John R ^b   McKeever, Tricia M ^c   Coward, William R ^a   Shale, Dennis J ^b   Johnson, Simon R ^a   Thornton, Jim G ^a   Harrison, Timothy W ^a   Knox, Alan J ^a   Bolton, Charlotte E ^a  

^a UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^b CARDIFF UNIVERSITY   (United Kingdom)

^c UNIVERSITY OF NOTTINGHAM   (United Kingdom)

Author keywords

Arterial stiffness; Chronic obstructive pulmonary disease; Stations

Indexed keywords

HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; SIMVASTATIN; ANTIINFLAMMATORY AGENT; AUTACOID; BIOLOGICAL MARKER; CARDIOVASCULAR AGENT; CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ADULT; AGED; ANTHROPOMETRY; ANTIINFLAMMATORY ACTIVITY; ARTERIAL STIFFNESS; ARTHRALGIA; ARTICLE; BLOOD PRESSURE; CARDIOVASCULAR EFFECT; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; CHEST INFECTION; CHOLESTEROL BLOOD LEVEL; CHRONIC OBSTRUCTIVE LUNG DISEASE; COMORBIDITY; CONTROLLED STUDY; COUGHING; DOUBLE BLIND PROCEDURE; DYSPNEA; FEMALE; FORCED EXPIRATORY VOLUME; FORCED VITAL CAPACITY; HUMAN; LUNG FUNCTION TEST; MAJOR CLINICAL STUDY; MALE; MYALGIA; PULSE WAVE; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY TRACT INFLAMMATION; SPIROMETRY; BLOOD; DRUG EFFECTS; ENGLAND; LUNG; MIDDLE AGED; PATHOPHYSIOLOGY; PNEUMONIA; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; TIME FACTOR; TREATMENT OUTCOME; VERY ELDERLY; VITAL CAPACITY;

AGED; AGED, 80 AND OVER; ANTI-INFLAMMATORY AGENTS; BIOMARKERS; CARDIOVASCULAR AGENTS; CHOLESTEROL; DOUBLE-BLIND METHOD; ENGLAND; FEMALE; FORCED EXPIRATORY VOLUME; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INFLAMMATION MEDIATORS; LUNG; MALE; MIDDLE AGED; PNEUMONIA; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; PULSE WAVE ANALYSIS; SIMVASTATIN; SPIROMETRY; TIME FACTORS; TREATMENT OUTCOME; VASCULAR STIFFNESS; VITAL CAPACITY;

EID: 84961294459     PISSN: 11769106     EISSN: 11782005     Source Type: Journal    
DOI: 10.2147/COPD.S76061     Document Type: Article

References (39)

1. Fabbri LM, Luppi F, Beghe B, Rabe KF. Complex chronic comorbidities of COPD. Eur Respir J. 2008;31(1):204–212.
2. Sin DD, Wu L, Man SF. The relationship between reduced lung function and cardiovascular mortality: a population-based study and a systematic review of the literature. Chest. 2005;127(6):1952–1959.
3. McGarvey LP, John M, Anderson JA, Zvarich M, Wise RA. Ascertainment of cause-specifc mortality in COPD: operations of the TORCH Clinical Endpoint Committee. Thorax. 2007;62(5):411–415.
4. Colhoun HM, Betteridge DJ, Durrington PN, et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet. 2004;364(9435): 685–696.
5. Soyseth V, Brekke PH, Smith P, Omland T. Statin use is associated with reduced mortality in COPD. Eur Respir J. 2007;29(2):279–283.
6. Mancini GB, Etminan M, Zhang B, et al. Reduction of morbidity and mortality by statins, angiotensin-converting enzyme inhibitors, and angiotensin receptor blockers in patients with chronic obstructive pulmonary disease. J Am Coll Cardiol. 2006;47(12):2554–2560.
7. Ridker PM, Danielson E, Fonseca FA, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008;359(21):2195–2207.
8. Laurent S, Boutouyrie P, Asmar R, et al. Aortic stiffness is an independent predictor of all-cause and cardiovascular mortality in hypertensive patients. Hypertension. 2001;37(5):1236–1241.
9. Ben-Shlomo Y, Spears M, Boustred C, et al. Aortic pulse wave velocity improves cardiovascular event prediction: an individual participant meta-analysis of prospective observational data from 17,635 subjects. J Am Coll Cardiol. 2014;63(7):636–646.
10. Sabit R, Bolton CE, Edwards PH, et al. Arterial stiffness and osteoporosis in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2007;175(12):1259–1265.
11. Maclay JD, McAllister DA, Mills NL, et al. Vascular dysfunction in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2009; 180(6):513–520.
12. Ferrier KE, Muhlmann MH, Baguet JP, et al. Intensive cholesterol reduction lowers blood pressure and large artery stiffness in isolated systolic hypertension. J Am Coll Cardiol. 2002;39(6):1020–1025.
13. Meng X, Qie L, Wang Y, Zhong M, Li L. Assessment of arterial stiffness affected by atorvastatin in coronary artery disease using pulse wave velocity. Clin Invest Med. 2009;32(6):E238.
14. Maki-Petaja KM, Booth AD, Hall FC, et al. Ezetimibe and simvastatin reduce infammation, disease activity, and aortic stiffness and improve endothelial function in rheumatoid arthritis. J Am Coll Cardiol. 2007; 50(9):852–858.
15. Sin DD, Lacy P, York E, Man SF. Effects of futicasone on systemic markers of infammation in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2004;170(7):760–765.
16. Miller J, Edwards LD, Agustí A, et al. Comorbidity, systemic infam-mation and outcomes in the ECLIPSE cohort. Respir Med. 2013;107(9): 1376–1384.
17. Wu YW, Kao HL, Huang CL, et al. The effects of 3-month atorvastatin therapy on arterial infammation, calcifcation, abdominal adipose tissue and circulating biomarkers. Eur J Nucl Med Mol Imaging. 2012;39(3): 399–407.
18. Criner GJ, Connett JE, Aaron SD, et al. Simvastatin for the prevention of exacerbations in moderate-to-severe COPD. N Engl J Med. 2014; 370(23):2201–2210.
19. Armitage J, Bowman L, Wallendszus K, et al. Intensive lowering of LDL cholesterol with 80 mg versus 20 mg simvastatin daily in 12,064 survivors of myocardial infarction: a double-blind randomised trial. Lancet. 2010;376(9753):1658–1669.
20. Laurent S, Cockcroft J, Van Bortel L, et al. Expert consensus document on arterial stiffness: methodological issues and clinical applications. Eur Heart J. 2006;27(21):2588–2605.
21. Crapo RO, Casaburi R, Coates AL, et al. ATS statement: guidelines for the six-minute walk test. Am J Respir Crit Care Med. 2002;166(1): 111–117.
22. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem. 1972;18(6):499–502.
23. Vlachopoulos C, Aznaouridis K, Stefanadis C. Prediction of cardiovascular events and all-cause mortality with arterial stiffness: a systematic review and meta-analysis. J Am Coll Cardiol. 2010;55(13): 1318–1327.
24. Van Bortel LM, Laurent S, Boutouyrie P, et al. Expert consensus document on the measurement of aortic stiffness in daily practice using carotid-femoral pulse wave velocity. J Hypertens. 2012;30(3):445–448.
25. Boutouyrie P, Hofman A, Verwoert GC, et al. Determinants of pulse wave velocity in healthy people and in the presence of cardiovascular risk factors: ‘establishing normal and reference values’. Eur Heart J. 2010;31(19):2338–2350.
26. Mancia G, Fagard R, Narkiewicz K, et al. 2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J. 2013;34(28):2159–2219.
27. John M, Hussain S, Prayle A, et al. Target renal damage: the microvas-cular associations of increased aortic stiffness in patients with COPD. Respir Res. 2013;14:31.
28. Dransfeld MT, Cockcroft JR, Townsend RR, et al. Effect of futicasone propionate/salmeterol on arterial stiffness in patients with COPD. Respir Med. 2011;105(9):1322–1330.
29. Sin DD, Man SFP. Why are patients with chronic obstructive pulmonary disease at increased risk of cardiovascular diseases? The potential role of systemic infammation in chronic obstructive pulmonary disease. Circulation. 2003;107(11):1514–1519.
30. Ridker PM, Rifai N, Rose L, Buring JE, Cook NR. Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of frst cardiovascular events. N Engl J Med. 2002;347(20): 1557–1565.
31. Pinto-Plata VM, Mullerova H, Toso JF, et al. C-reactive protein in patients with COPD, control smokers and non-smokers. Thorax. 2006;61(1): 23–28.
32. Lowrey GE, Henderson N, Blakey JD, Corne JM, Johnson SR. MMP-9 protein level does not refect overall MMP activity in the airways of patients with COPD. Respir Med. 2008;102(6):845–851.
33. Basta G. Receptor for advanced glycation endproducts and atherosclerosis: from basic mechanisms to clinical implications. Atherosclerosis. 2008;196(1):9–21.
34. O’Driscoll G, Green D, Taylor RR. Simvastatin, an HMG-coenzyme A reductase inhibitor, improves endothelial function within 1 month. Circulation. 1997;95(5):1126–1131.
35. Mason RP, Walter MF, Jacob RF. Effects of HMG-CoA reductase inhibitors on endothelial function: role of microdomains and oxidative stress. Circulation. 2004;109(21 Suppl 1):II34–II41.
36. Lee TM, Lin MS, Chang NC. Usefulness of C-reactive protein and interleukin-6 as predictors of outcomes in patients with chronic obstructive pulmonary disease receiving pravastatin. Am J Cardiol. 2008;101(4):530–535.
37. Yasmin, McEniery CM, Wallace S, et al. Matrix metalloproteinase-9 (MMP-9), MMP-2, and serum elastase activity are associated with systolic hypertension and arterial stiffness. Arterioscler Thromb Vasc Biol. 2005;25(2):372.
38. Coulson JM, Rudd JHF, Duckers JM, et al. Excessive aortic infamma-tion in chronic obstructive pulmonary disease: an 18F-FDG PET pilot study. J Nucl Med. 2010;51(9):1357–1360.
39. Alexeeff SE, Litonjua AA, Sparrow D, Vokonas PS, Schwartz J. Statin use reduces decline in lung function: VA Normative Aging Study. Am J Respir Crit Care Med. 2007;176(8):742–747.